Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Kirby, M.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

ASCOT — lipid lowering arm

Mike Kirby

The Surgery, Nevells Road, Letchworth, SG6 4TS, UK, kirbym{at}globalnet.co.uk

The Anglo-Scandinavian Cardiac Outcomes Lipid Lowering Arm (ASCOT-LLA) has recently been terminated early due to significant reductions in major cardiovascular events amongst patients taking atorvastatin. This article summarises the study and considers its implications for clinical practice.

Key Words: type 2 diabetes • atorvastatin • ASCOT.

The British Journal of Diabetes & Vascular Disease, Vol. 3, No. 3, 200-201 (2003)
DOI: 10.1177/14746514030030030701
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 British Journal of Diabetes & Vascular DiseaseHome page
R. W Mccallum and M. Fisher
From 4S to FIELD and PROactive: 10 years of CV trials in people with diabetes
The British Journal of Diabetes & Vascular Disease, July 1, 2005; 5(4): 218 - 225.
[Abstract] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
M. Kirby
Has ASCOT signalled the end for beta blockers as first-line antihypertensive agents?
The British Journal of Diabetes & Vascular Disease, March 1, 2005; 5(2): 100 - 102.
[Abstract] [PDF]